Payment overview · 2025
General Payments
$525.63
16 reported records · 5 companies
Healthcare provider profile · identity verified
Brian Lair, DO
Allopathic & Osteopathic Physicians|Family Medicine · RED BLUFF, CA · NPI 1356476196
Verified facts
What the public records show
CMS Open Payments records show Brian Lair, DO received $525.63 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 64.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $340.09 | 64.7% | 12 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $119.07 | 22.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.90 | 4.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $21.92 | 4.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $19.65 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.63 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $170.62 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $143.48 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $119.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.99 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $9.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 306 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 134 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 35 |
| Lisinopril | Lisinopril | 116 | 35 |
| Losartan Potassium | Losartan Potassium | 111 | 32 |
| Metformin Hcl | Metformin Hcl | 97 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 28 |
| Tramadol Hcl | Tramadol Hcl | 86 | 14 |
| Trulicity | Dulaglutide | 83 | 12 |
| Gabapentin | Gabapentin | 78 | 27 |
| Furosemide | Furosemide | 76 | 26 |
| Omeprazole | Omeprazole | 76 | 22 |
| Ezetimibe | Ezetimibe | 68 | 22 |
| Potassium Chloride | Potassium Chloride | 68 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 16 |
| Liothyronine Sodium | Liothyronine Sodium | 58 | 18 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 56 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | suppressed |
| Carvedilol | Carvedilol | 55 | 16 |
| Pregabalin | Pregabalin | 54 | 11 |
| Meloxicam | Meloxicam | 52 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 17 |
| Azithromycin | Azithromycin | 48 | 11 |
| Jardiance | Empagliflozin | 48 | 13 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Progesterone | Progesterone, Micronized | 48 | 15 |
| Celecoxib | Celecoxib | 46 | 11 |
| Ozempic | Semaglutide | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 18 |
| Clonidine Hcl | Clonidine Hcl | 44 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 12 |
| Methadone Hcl | Methadone Hcl | 41 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 14 |
| Farxiga | Dapagliflozin Propanediol | 40 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Irbesartan | Irbesartan | 39 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 11 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 12 |
| Simvastatin | Simvastatin | 37 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 36 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Torsemide | Torsemide | 36 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Estradiol | Estradiol | 31 | 13 |
| Famotidine | Famotidine | 31 | 11 |
| Insulin Lispro | Insulin Lispro | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 14 |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Acarbose | Acarbose | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 15 |
| Fluconazole | Fluconazole | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Nystatin | Nystatin | 25 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 11 |
| Nabumetone | Nabumetone | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 11 |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.63 · 16 records | ABBVIE INC. | ABRYSVO, COMIRNATY, CREON, NEXPLANON, PREVNAR 20, QULIPTA, SAPIEN 3 Ultra RESILIA, SUBLOCADE, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error